DOI:10.1111/j.1365-2125.2004.02166.x

AUTHOR INDEX

AARONS, L. *see* MITHWANI, S.
AARONS, L. *see* PITSIU, M.
AHERNE, Z. *see* BLAKEY, G.E.
AKHONDZADEH, S., MOHAMMADI, M.R., ERFANI, S., TEHRANIDOOST, M., AMINI, H. & KASHANI, L. A clinical trial of adjunctive cyproheptadine in the treatment of autistic disorder: a double-blind and placebo controlled trial: 670
AKHONDZADEH, S., MOHAMMADI, M.R., MAHAGERI, H., AMINI, H. & KASHANI, L. Ritanserin as an adjunct to lithium and haloperidol for the treatment of patients with acute mania: a double-blind and placebo controlled trial: 674
AKICI, A., KALAÇA, S., UGURLU, M.Ü., KARAALP, A., ÇALI, Ş. & OKTAY, Ş. Impact of a short postgraduate course in rational pharmacotherapy for general practitioners: 310
AKIZAWA, T. *see* OHASHI, N.
AKTAN, Y. *see* ÖZDEMIR, M.
ALBRECHT, S. *see* IHMSEN, H.
ALLEGAERT, K., VERBESSELT, R., DEVLIEGER, H., DE HOON, J. & TIBBOEL, D. Cerebrospinal fluid pharmacokinetics of paracetamol after intravenous propacetamol in a preterm infant: 224
ALLEGRE, T. *see* SOLAS, C.
ALLEN, K.M. *see* DOOLEY, M.J.
AMINI, H. *see* AKHONDZADEH, S.
AMMIT, A.J. *see* JIANG, X.
ANDOH, N. *see* MINAMI, J.
ANTILA, S., KIVIKKO, M., LEHTONEN, L., EHA, J., HEIKKILÄ, A., POHJANJOUSI, P. & PENTIKÄINEN, P.J. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan: 412
ARAKI, N. *see* TSURUOKA, S.
ARONSON, J.K. *see* GRAHAME-SMITH, D.G.
ARONSON, J.K. *see* LOKE, Y.K.
ARONSON, J.K. Drug interactions – information, education, and the *British National Formulary*: 371
ARONSON, J.K. In defence of polypharmacy: 119
ARONSON J.K. On Being 30: 1
ARONSON, J.K. On the waterfront – the breadth and depth of clinical pharmacology: 693
ARONSON, J.K. Rational prescribing, appropriate prescribing: 229
ARSHAD, S. *see* NORRIS, V.
ATTHOBARI, J., MONSTER, T.B.M., DE JONG, P.E., DE JONG-VAN DEN BERG FOR THE PREVEND STUDY GROUP, L.T.W. The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs: 328
ATTINÀ, T., OLIVER, J.J. & WEBB, D.J. Investigation of the effects of inhaled tiotropium on the response to acetylcholine in the forearm vasculature: 681
AYNACIOGLU, A.S., NACAK, M., FILIZ, A., EKINCI, E. & ROOTS, I. Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma: 213

BÅÅTHE, S. *see* JOHNSTON, D.
BAAS, P. *see* DE JONGE, M.E.
BACK, D.J. *see* HARTKOORN, R.C.
BACKMAN, J.T. *see* GRANFORS, M.T.
BACKMAN, J.T. *see* KYRKLUND, C.
BACKMAN, J.T. *see* NIEMI, M.
BARILLA, D. *see* KOVARIK, J.M.
BARTELINK, I.H., BRÜGGEMANN, R.J.M., VAN ASSELT, G.J., OVERDIEK, J.W.P.M., BOERMANS, P.A.M.M. & OOSTVOGEL, P.M. Improving the quality of antibiotic treatment in a Dutch hospital: 355
BATEMAN, D.N. *see* STRACHAN, E.M.
BATES, C.E. *see* LEE, D.K.C.
BATTY, G.M. *see* JACKSON, S.H.D.
BATTY, K.T., ILETT, K.F. & DAVIS, T.M.E. Protein binding and α:β anomer ratio of dihydroartemisinin *in vivo*: 529
BÉGAUD, B. *see* MARTIN, K.
BECK, C.R., YEO, W.W. & ROWLAND YEO, K. Cost-effectiveness of smoking cessation therapy compared with statins to prevent cardiovascular events: 689
BEIJNEN, J.H. *see* CROMMENTUYN, K.M.L.
BEIJNEN, J.H. *see* DE JONGE, M.E.
BEIJNEN, J.H. *see* KUPPENS, I.E.L.M.
BELLMANN, R., KUCHLING, G., DEHGHANYAR, P., ZEITLINGER, M., MINAR, E., MAYER, B.X., MÜLLER, M. & JOUKHADAR, C. Tissue pharmacokinetics of levofloxacin in human soft tissue infections: 563
BELTMAN, F.W. *see* GREVING, J.P.
BENNETT, K. *see* FITZ-SIMON, N.
BENNETT, K. *see* ODUBANJO, E.
BENNETT, K. *see* TEELING, M.
BENNETT, K. *see* USHER, C.
BENNETT, K. *see* WILLIAMS, D.
BENNETT, K., O'CONNOR, H., THORNTON, O., DOBSON, M., BUCKLEY, M.J., O'MORAIN, C., QUASIM, A. & FEELY, J. Underuse of eradication therapy following *Helicobacter pylori* testing: 666
BENNETT, P.N. & BROWN, M.J. Clinical Pharmacology: 223
BERRY, N.S. *see* PERSKY, A.M.
BEUDEKER, Q.H. *see* OLIVER, J.J.
BJARNASON, I.T., CHARLETT, A., DOBBS, R.J., DOBBS, S.M., OWEN, R.J., OXLADE, N., PRICE, A.B. & WELLER, C. Response of gait in idiopathic parkinsonism to *Helicobacter pylori* eradication: 689
BLACK, J. *see* BOYCE, M.
BLAIR, E.Y.L. *see* SLAVIERO, K.A.
BLAIR, E.Y.L., RIVORY, L.P., CLARKE, S.J. & MCLACHLAN, A.J. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours: 416
BLAKEY, G.E., LOCKTON, J.A., PERRETT, J., NORWOOD, P., RUSSELL, M., AHERNE, Z. & PLUME, J. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1: 162
BOCHNER, F. *see* FOSTER, D.J.R.
BODENSTEIN, J. *see* BRINK, C.B.
BOERMANS, P.A.M.M. *see* BARTELINK, I.H.
BOLK, J.H. *see* FRANSON, K.L.
BONAR, H.L. *see* DISHY, V.
BOSCH, D.A. *see* MERKUS, P.
BOSCH, T.M. *see* KUPPENS, I.E.L.M.
BOUW, R. *see* EDEROTH, P.
BOWLER, A. *see* OLIVER, J.J.
BOYCE, M. *see* CALDER, N.
BOYCE, M. *see* NORRIS, V.
BOYCE, M., WARRINGTON, S., NENTWICH, H., NORRIS, V., HULL, R. & BLACK, J., Effect of repeated doses of Yf476, a gastrin antagonist, on pentagastrin-induced changes in volume, H^+ content and pH of gastric aspirate in healthy subject: 684
BOYD, K.M. *see* CARLSON, R.V.
BRATER, D.C. *see* MACFADYEN, R.J.
BRETT, S.E., RITTER, J.M., TURNER, C. & CHOWIENCZYK, P.J. An acute elevation of homocysteine by methionine loading increases exercise but not resting blood pressure: 672
BRIEN, J.E. *see* EASTON, K.L.
BRIGHT, J. *see* DOOLEY, M.J.

© 2004 Blackwell Publishing Ltd

DOI:10.1111/j.1365-2125.2004.02166.x

AUTHOR INDEX

AARONS, L. *see* MITHWANI, S.
AARONS, L. *see* PITSIU, M.
AHERNE, Z. *see* BLAKEY, G.E.
AKHONDZADEH, S., MOHAMMADI, M.R., ERFANI, S., TEHRANIDOOST, M., AMINI, H. & KASHANI, L. A clinical trial of adjunctive cyproheptadine in the treatment of autistic disorder: a double-blind and placebo controlled trial: 670
AKHONDZADEH, S., MOHAMMADI, M.R., MAHAGERI, H., AMINI, H. & KASHANI, L. Ritanserin as an adjunct to lithium and haloperidol for the treatment of patients with acute mania: a double-blind and placebo controlled trial: 674
AKICI, A., KALAÇA, S., UGURLU, M.Ü., KARAALP, A., ÇALI, Ş. & OKTAY, Ş. Impact of a short postgraduate course in rational pharmacotherapy for general practitioners: 310
AKIZAWA, T. *see* OHASHI, N.
AKTAN, Y. *see* ÖZDEMIR, M.
ALBRECHT, S. *see* IHMSEN, H.
ALLEGAERT, K., VERBESSELT, R., DEVLIEGER, H., DE HOON, J. & TIBBOEL, D. Cerebrospinal fluid pharmacokinetics of paracetamol after intravenous propacetamol in a preterm infant: 224
ALLEGRE, T. *see* SOLAS, C.
ALLEN, K.M. *see* DOOLEY, M.J.
AMINI, H. *see* AKHONDZADEH, S.
AMMIT, A.J. *see* JIANG, X.
ANDOH, N. *see* MINAMI, J.
ANTILA, S., KIVIKKO, M., LEHTONEN, L., EHA, J., HEIKKILÄ, A., POHJANJOUSI, P. & PENTIKÄINEN, P.J. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan: 412
ARAKI, N. *see* TSURUOKA, S.
ARONSON, J.K. *see* GRAHAME-SMITH, D.G.
ARONSON, J.K. *see* LOKE, Y.K.
ARONSON, J.K. Drug interactions – information, education, and the *British National Formulary*: 371
ARONSON, J.K. In defence of polypharmacy: 119
ARONSON J.K. On Being 30: 1
ARONSON, J.K. On the waterfront – the breadth and depth of clinical pharmacology: 693
ARONSON, J.K. Rational prescribing, appropriate prescribing: 229
ARSHAD, S. *see* NORRIS, V.
ATTHOBARI, J., MONSTER, T.B.M., DE JONG, P.E., DE JONG-VAN DEN BERG FOR THE PREVEND STUDY GROUP, L.T.W. The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs: 328
ATTINÀ, T., OLIVER, J.J. & WEBB, D.J. Investigation of the effects of inhaled tiotropium on the response to acetylcholine in the forearm vasculature: 681
AYNACIOGLU, A.S., NACAK, M., FILIZ, A., EKINCI, E. & ROOTS, I. Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma: 213

BÅÅTHE, S. *see* JOHNSTON, D.
BAAS, P. *see* DE JONGE, M.E.
BACK, D.J. *see* HARTKOORN, R.C.
BACKMAN, J.T. *see* GRANFORS, M.T.
BACKMAN, J.T. *see* KYRKLUND, C.
BACKMAN, J.T. *see* NIEMI, M.
BARILLA, D. *see* KOVARIK, J.M.
BARTELINK, I.H., BRÜGGEMANN, R.J.M., VAN ASSELT, G.J., OVERDIEK, J.W.P.M., BOERMANS, P.A.M.M. & OOSTVOGEL, P.M. Improving the quality of antibiotic treatment in a Dutch hospital: 355
BATEMAN, D.N. *see* STRACHAN, E.M.
BATES, C.E. *see* LEE, D.K.C.
BATTY, G.M. *see* JACKSON, S.H.D.
BATTY, K.T., ILETT, K.F. & DAVIS, T.M.E. Protein binding and α:β anomer ratio of dihydroartemisinin *in vivo*: 529
BÉGAUD, B. *see* MARTIN, K.
BECK, C.R., YEO, W.W. & ROWLAND YEO, K. Cost-effectiveness of smoking cessation therapy compared with statins to prevent cardiovascular events: 689
BEIJNEN, J.H. *see* CROMMENTUYN, K.M.L.
BEIJNEN, J.H. *see* DE JONGE, M.E.
BEIJNEN, J.H. *see* KUPPENS, I.E.L.M.
BELLMANN, R., KUCHLING, G., DEHGHANYAR, P., ZEITLINGER, M., MINAR, E., MAYER, B.X., MÜLLER, M. & JOUKHADAR, C. Tissue pharmacokinetics of levofloxacin in human soft tissue infections: 563
BELTMAN, F.W. *see* GREVING, J.P.
BENNETT, K. *see* FITZ-SIMON, N.
BENNETT, K. *see* ODUBANJO, E.
BENNETT, K. *see* TEELING, M.
BENNETT, K. *see* USHER, C.
BENNETT, K. *see* WILLIAMS, D.
BENNETT, K., O'CONNOR, H., THORNTON, O., DOBSON, M., BUCKLEY, M.J., O'MORAIN, C., QUASIM, A. & FEELY, J. Underuse of eradication therapy following *Helicobacter pylori* testing: 666
BENNETT, P.N. & BROWN, M.J. Clinical Pharmacology: 223
BERRY, N.S. *see* PERSKY, A.M.
BEUDEKER, Q.H. *see* OLIVER, J.J.
BJARNASON, I.T., CHARLETT, A., DOBBS, R.J., DOBBS, S.M., OWEN, R.J., OXLADE, N., PRICE, A.B. & WELLER, C. Response of gait in idiopathic parkinsonism to *Helicobacter pylori* eradication: 689
BLACK, J. *see* BOYCE, M.
BLAIR, E.Y.L. *see* SLAVIERO, K.A.
BLAIR, E.Y.L., RIVORY, L.P., CLARKE, S.J. & MCLACHLAN, A.J. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours: 416
BLAKEY, G.E., LOCKTON, J.A., PERRETT, J., NORWOOD, P., RUSSELL, M., AHERNE, Z. & PLUME, J. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1: 162
BOCHNER, F. *see* FOSTER, D.J.R.
BODENSTEIN, J. *see* BRINK, C.B.
BOERMANS, P.A.M.M. *see* BARTELINK, I.H.
BOLK, J.H. *see* FRANSON, K.L.
BONAR, H.L. *see* DISHY, V.
BOSCH, D.A. *see* MERKUS, P.
BOSCH, T.M. *see* KUPPENS, I.E.L.M.
BOUW, R. *see* EDEROTH, P.
BOWLER, A. *see* OLIVER, J.J.
BOYCE, M. *see* CALDER, N.
BOYCE, M. *see* NORRIS, V.
BOYCE, M., WARRINGTON, S., NENTWICH, H., NORRIS, V., HULL, R. & BLACK, J., Effect of repeated doses of Yf476, a gastrin antagonist, on pentagastrin-induced changes in volume, H^+ content and pH of gastric aspirate in healthy subject: 684
BOYD, K.M. *see* CARLSON, R.V.
BRATER, D.C. *see* MACFADYEN, R.J.
BRETT, S.E., RITTER, J.M., TURNER, C. & CHOWIENCZYK, P.J. An acute elevation of homocysteine by methionine loading increases exercise but not resting blood pressure: 672
BRIEN, J.E. *see* EASTON, K.L.
BRIGHT, J. *see* DOOLEY, M.J.

© 2004 Blackwell Publishing Ltd

BRINK, C.B., HARVEY, B.H., BODENSTEIN, J., VENTER, D.P. & OLIVER, D.W. Recent advances in drug action and therapeutics: Relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology: 373
BROUWER, K.L.R. *see* PERSKY, A.M.
BROUWERS, J.R.B.J. *see* DENEER, V.H.M.
BROUWERS, J.R.B.J. *see* VAN ROON, E.N.
BROUWERS, J.R.B.J. *see* WILTING, I.
BROWN, H.S. *see* ITO, K.
BROWN, M.J. *see* BENNETT, P.N.
BRÜGGEMANN, R.J.M. *see* BARTELINK, I.H.
BRUYN, G.A.W. *see* VAN ROON, E.N.
BRYANT, C.A. *see* FORD, G.A.
BÜHRMANN, S. *see* WENZEL, R.R.
BUCKLEY, M.J. *see* BENNETT, K.
BURGGRAAF, J. *see* KAMERLING, I.M.C.
BURHENNE, J. *see* FRÖHLICH, M.

ÇALI, Ş. *see* AKICI, A.
CALDER, N., BOYCE, M., POSNER, J. & SCIBERRAS, D. Clinical pharmacology studies in UK Phase 1 units: an AHPPI survey 1999–2000: 76
CAMPBELL-O'SULLIVAN, S.P. *see* GREENHAFF, P.L.
CANTARINI, M.V., WATKINS, C.L., GROWCOTT, J. & HUGHES, A.M. An investigation of components of variance and tachyphylaxis in a placebo-controlled intravenous tyramine study: 657
CAREY, D.L. *see* DOOLEY, M.J.
CARLSON, R.V., BOYD, K.M. & WEBB, D.J. The revision of the Declaration of Helsinki: past, present and future: 695
CARTWRIGHT, C.S., SAVAGE, C.M. & LENNARD, L. Concordance of thiopurine methyltransferase genotype and phenotype in childhood leukaemia: 685
CATE, T.T. *see* OLIVER, J.J.
CHAMBERLAIN, P.J. *see* NAISBITT, D.J.
CHAN, C. *see* HUA, T.C.
CHANDLER, B. *see* HARTKOORN, R.C.
CHAPMAN, C.B. *see* EASTON, K.L.
CHARLESWORTH, B.R. *see* KÅGEDAL, M.
CHARLETT, A. *see* BJARNASON, I.T.
CHEMLA, C. *see* TRENQUE, T.
CHESTER, N., MOTTRAM, D.R., REILLY, T. & POWELL, M. Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control: 62
CHEUNG, B.M.Y., LAUDER, I.J., LAU, C.-P. & KUMANA, C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes: 640
CHOONG, L. *see* NORRIS, V.
CHOWIENCZYK, P.J. *see* BRETT, S.E.; RAMBARAN, C.
CHUI, J., TORDOFF, J., KENNEDY, J. & REITH, D. Trends in accessibility to medicines for children in New Zealand: 1998–2002: 322
CLARKE, S.J. *see* BLAIR, E.Y.L.
CLARKE, S.J. *see* SLAVIERO, K.A.
CLELAND, J.G.F. *see* MORANT, S.V.
COHEN, A.F. *see* FRANSON, K.L.
COHEN, A.F. *see* KAMERLING, I.M.C.
COLLER, J.K. *see* DAVIES, B.J.L.
COLLER, J.K. *see* HUTCHINSON, M.R.
COLLER, J.K., KREBSFAENGER, N., KLEIN, K., WOLBOLD, R., NÜSSLER, A., NEUHAUS, P., ZANGER, U.M., EICHELBAUM, M. & MÜRDTER, T.E. Large interindividual variability in the *in vitro* formation of tamoxifen metabolites related to the development of genotoxicity: 105
COLLET, J.-P. *see* QUACH, C.
CONSTANTIN-TEODOSIU, D. *see* GREENHAFF, P.L.
CORDEN, Z. *see* NORRIS, V.
CORNET, F. *see* FRANSON, K.L.
CORTI, R. *see* WORTHLEY, M.I.
COURTNEY, R., WEXLER, D., RADWANSKI, E., LIM, J. & LAUGHLIN, M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults: 218
COWAN, C. *see* PURKINS, L.
CREWE, H.K. *see* ÖZDEMIR, M.
CROMMENTUYN, K.M.L., HUITEMA, A.D.R., VAN HEESWIJK, R.P.G., MATHÔT, R.A.A., SCHERPBIER, H.J., KUIJPERS, T.W. & BEIJNEN, J.H. Population pharmacokinetics of nelfinavir in hiv-1-infected children: 355
CRUDEN, N.L., WITHEROW, F.N., JOHNSTON, N.R., WEBB, D.J., FOX, K.A.A. & NEWBY, D.E. Bradykinin contributes to the systemic haemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure: 671
CURRIE, G.P. *see* LEE, D.K.C.

DALE, M.M. *see* RANG, H.P.
DALY, A.K. *see* KAMALI, F.
DALY, A.K. & KING B.P. *CYP3A5* phenotype-genotype correlations in a British population: 664
DANHOF, M. *see* SWART, E.L.
DAVEY, P.G. *see* MORANT, S.V.
DAVIES, B.J.L., COLLER, J.K., JAMES, H.M., GILLIS, D., SOMOGYI, A.A., HOROWITZ, J.D., MORRIS, R.G. & SALLUSTIO, B.C. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline: 456
DAVIES, S.J.C., EAYRS, S., PRATT, P. & LENNARD, M.S. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards: 464
DAVIS, T.M.E. *see* BATTY, K.T.
DAVIS, T.M.E. *see* HUNG, T.-Y.
DAVIS, T.M.E. *see* KARUNAJEEWA, H.
DAY, R.O. *see* JIANG, X.
DE BOER, A. *see* MAITLAND-VAN DER ZEE, A.H.
DE BOER, A. *see* MANTEL-TEEUWISSE, A.K.
DE BOER, A. *see* REIJNTJENS, S.
DE BOER, A. *see* SCHELLEMAN, H.
DE BRABANDER, C. *see* VAN DEN ABEELE, W.M.
DE HOON, J. *see* ALLEGAERT, K.
DE HOON, J.N.J.M. *see* VANMOLKOT, F.H.M.
DE JONG, P.E. *see* ATTHOBARI, J.
DE JONGE, M.E., VAN DEN BONGARD, H.J.G.D., HUITEMA, A.D.R., MATHÔT, R.A.A., ROSING, H., VAN MAANEN, R., KOOPMAN-KROON, C., BAAS, P., VAN ZANDWIJK, N., KEESSEN, M., RODENHUIS, S., BEIJNEN, J.H. & SCHELLENS, J.H.M. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer: 356
DE JONGH, J. *see* SWART, E.L.
DE JONG-VAN DEN BERG FOR THE PREVEND STUDY GROUP, L.T.W. *see* ATTHOBARI, J.
DE KAM, M.L. *see* KAMERLING, I.M.C.
DE LAET, C.E.D.H. *see* SCHOOFS, M.W.C.J.
DE LONGUEVILLE, M. *see* PITSIU, M.
DE NIET, S. *see* MALONNE, H.
DE SMET, P.A.G.M. *see* VISSER, L.E.
DE VRIES, R. *see* YASUI-FURUKORI, N.
DEGENER, J.E. *see* MOL, P.G.M.
DEGRAEUWE, P.L.J. *see* REIJNTJENS, S.
DEHGHANYAR, P. *see* BELLMANN, R.
DENEER, V.H.M., KINGMA, J.H., LIE-A-HUEN, L., PROOST, J.H., VAN HEMEL, N.M., UYTDEHAAG, G.M.M., DUNSELMAN, P.H.J.M., STUURMAN, A. & BROUWERS, J.R.B.J. Cardioversion of atrial fibrillation with a loading dose of flecainide tablets or an oral solution of a mixture of flecainide and cisapride: 356
DENIG, P. *see* GREVING, J.P.
DENIG, P. *see* MOL, P.G.M.
DENIG, P., SCHAARS, C.F., KASJE, W.N. & HAAIJER-RUSKAMP, F.M. Patient, doctor, and organisational factors affecting hypertension management in patients with type 2 diabetes: 357
DENIS, M.B. *see* HUNG, T.-Y.
DENIS, M.B. *see* KARUNAJEEWA, H.

DENVIR, M.A. *see* LESLIE, S.J.
DEPLANQUE, D., LEYS, D., PARNETTI, L., SCHMIDT, R., FERRO, J., REUCK, J.D., MAS, J.-L. & GALLAI, V. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study: 798
DERRY, S. *see* LOKE, Y.K.
DEVLIEGER, H. *see* ALLEGAERT, K.
DHIVER, C. *see* SOLAS, C.
DINGEMANSE, J. & VAN GIERSBERGEN, P.L.M. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile: 344
DISHY, V., HARRIS, P.A., PIERCE, R., PRASAD, H.C., SOFOWORA, G., BONAR, H.L., WOOD, A.J.J. & STEIN, C.M. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers: 209
DITTERS, J.M. *see* VAN RIEMSDIJK, M.M.
DOBBS, N.A. *see* RALPH, L.D.
DOBBS, R.J. *see* BJARNASON, I.T.
DOBBS, S.M. *see* BJARNASON, I.T.
DOBSON, M. *see* BENNETT, K.
DOECKE, C.J. *see* DOOLEY, M.J.
DONNELLY, R. Characterizing variability in cardiovascular drug responses: 535
DOOLEY, M.J., ALLEN, K.M., DOECKE, C.J., GALBRAITH, K.J., TAYLOR, G.R., BRIGHT, J. & CAREY, D.L. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals: 513
DROGOUL, M.-P. *see* SOLAS, C.
DUBOIS, E.A. *see* FRANSON, K.L.
DUKE, C.C. *see* JIANG, X.
DUMONT, G.J.H., OOSTERINK, B.J., PALTANSING, S., VAN BURGEL, N., VAN DER LINDEN, M., SCHOEMAKER, R. & VAN GERVEN, J.M.A. Determination of alcohol infusion rate by clamping of breath alcohol concentration – a comparison with modelled infusion regimens based on individual pharmacokinetics: 357
DUNSELMAN, P.H.J.M. *see* DENEER, V.H.M.
DUPOUY, D. *see* TRENQUE, T.
DURAND, A. *see* SOLAS, C.
DUVAUCHELLE, T. *see* KÅGEDAL, M.

EASTON, K.L., CHAPMAN, C.B. & BRIEN, J.E. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics: 611
EAYRS, S. *see* DAVIES, S.J.C.
EDEROTH, P., TUNBLAD, K., BOUW, R., LUNDBERG, C.J.F., UNGERSTEDT, U., NORDSTRÖM, C.-H. & HAMMARLUND-UDENAES, M. Blood–brain barrier transport of morphine in patients with severe brain trauma: 427
EDWARDS, G. *see* MITHWANI, S.
EGBERTS, A.C.G. *see* WILTING, I.
EHA, J. *see* ANTILA, S.
EICHELBAUM, M. *see* COLLER, J.K.
EKINCI, E. *see* AYNACIOGLU, A.S.
EKINS-DAUKES, S. *see* KRISHNAMOORTHY, N.
EKINS-DAUKES, S. *see* NOVAK, P.
EKINS-DAUKES, S. *see* TANAKA, M.
ERFANI, S. *see* AKHONDZADEH, S.
ERIKSSON U.G. *see* JOHNSTON, D.
EVE, M.D. *see* PURKINS, L.

FARDON, T.C. *see* LEE, D.K.C.
FARRELL, J. *see* NAISBITT, D.J.
FARRELL, J. *see* WU, Y.
FARRELL, J., GIBNEY, C.A., PIRMOHAMED, M., PARK, B.K. & NAISBITT, D.J. Characterization of drug-specific CD4+ T-cells expressing the skin homing receptor CCR10 in lamotrigine hypersensitivity: 690
FEELY, J. *see* BENNETT, K.
FEELY, J. *see* FITZ-SIMON, N.
FEELY, J. *see* MAHMUD, A.
FEELY, J. *see* MCNULTY, M.
FEELY, J. *see* ODUBANJO, E.
FEELY, J. *see* TEELING, M.
FEELY, J. *see* USHER, C.
FEELY, J. *see* WILLIAMS, D.
FERRO, J. *see* DEPLANQUE, D.
FILIZ, A. *see* AYNACIOGLU, A.S.
FITZPATRICK, A. *see* KUPPENS, I.E.L.M.
FITZ-SIMON, N., BENNETT, K. & FEELY, J. A model for the probability of discontinuation of antihypertensive therapy: 682
FORD, G.A., BRYANT, C.A., MANGONI, A.A. & JACKSON, S.H.D. Stroke, dementia, and drug delivery: 15
FORRESTER, T. *see* RAMBARAN, C.
FOSTER, D.J.R. *see* HUTCHINSON, M.R.
FOSTER, D.J.R., SOMOGYI, A.A., WHITE, J.M. & BOCHNER, F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients: 742
FOURRIER, A. *see* MARTIN, K.
FOX, K.A.A. *see* CRUDEN, N.L.
FRANCES, C., HOIZEY, G., MILLART, H. & TRENQUE, T. Paediatric methylphenidate (Ritalin®) restrictive conditions of prescription in France: 115
FRANSON, K.L., DUBOIS, E.A., VAN GERVEN, J.M.A., CORNET, F., BOLK, J.H. & COHEN, A.F. Teaching resource centre (TRC): teaching clinical pharmacology in an integrated medical school curriculum: 358
FREARSON, R. *see* KAMALI, F.
FRÖHLICH, M., BURHENNE, J., MARTIN-FACKLAM, M., WEISS, J., VON WOLFF, M., STROWITZKI, T., WALTER-SACK, I. & HAEFELI, W.E. Oral contraception does not alter single dose saquinavir pharmacokinetics in women: 244
FUJIMURA, A. *see* TSURUOKA, S.
FUKAZAWA, I., UCHIDA, N., UCHIDA, E. & YASUHARA, H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese: 448

GALBRAITH, K.J. *see* DOOLEY, M.J.
GALLAI, V. *see* DEPLANQUE, D.
GAN, S.H., ISMAIL, R., WAN ADNAN, W.A., ZULMI, W., KUMARASWAMY, N. & LARMIE, E.T. Relationship between Type A and B personality and debrisoquine hydroxylation capacity: 785
GANS, R.O.B. *see* MOL, P.G.M.
GIBNEY, C.A. *see* FARRELL, J.
GILLIS, D. *see* DAVIES, B.J.L.
GLEESON, M. *see* ZAHIR, H.
GOETTSCH, W.G. *see* MANTEL-TEEUWISSE, A.K.
GOGGIN, T., NGUYEN, Q.T.X. & MUNAFO, A. Population pharmacokinetic modelling of Emfilermin (recombinant human ieukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing *in vitro* fertilization and embryo transfer: 576
GONZALES, C.R. *see* HUA, T.C.
GORSKI, J.C. *see* MACFADYEN, R.J.
GRAHAME-SMITH, D.G., ARONSON, J.K. Oxford Textbook of Clinical Pharmacology and Drug Therapy: 112
GRANFORS, M.T., BACKMAN, J.T., LAITILA, J. & NEUVONEN, P.J. Tizanidine is mainly metabolized by cytochrome P450 1A2 *in vitro*: 349
GREENHAFF, P.L., CAMPBELL-O'SULLIVAN, S.P., CONSTANTIN-TEODOSIU, D., POUCHER, S.M., ROBERTS, P.A. & TIMMONS, J.A. Metabolic inertia in contracting skeletal muscle: a novel approach for pharmacological intervention in peripheral vascular disease: 237
GREVING, J.P., DENIG, P., VAN DER VEEN, W.J., BELTMAN, F.W., STURKENBOOM, M.C.J.M. & HAAIJER-RUSKAMP, F.M. Trends in antihypertensive drug prescribing in dutch general practice from 1996 to 2000: 359
GRIEP, E.N. *see* VAN ROON, E.N.
GRIFFIN, J.P. & O'GRADY, J. The Regulation of Medical Products: 113
GRIND, M. *see* JOHNSTON, D.

GROENEVELD, G.J. *see* VAN KAN, H.J.M.
GROWCOTT, J. *see* CANTARINI, M.V.
GUCHELAAR, H.J. *see* MERKUS, P.
GUCHELAAR, H.J. *see* VAN KAN, H.J.M.
GUILLAUME, C. *see* REIJNTJENS, S.

HAAIJER-RUSKAMP, F.M. *see* DENIG, P.
HAAIJER-RUSKAMP, F.M. *see* GREVING, J.P.
HAAIJER-RUSKAMP, F.M. *see* MOL, P.G.M.
HAEFELI, W.E. *see* FRÖHLICH, M.
HAEFELI, W.E. *see* MARTIN-FACKLAM, M.
HAEFELI, W.E. *see* WEISS, J.
HALL, I.P. *see* LEE, D.K.C.
HAMMARLUND-UDENAES, M. *see* EDEROTH, P.
HAMRÉN, B. *see* JOHNSTON, D.
HANNAFORD, P.J. *see* SIMPSON, C.R.
HARADA, K. *see* TSURUOKA, S.
HARRIS, P.A. *see* DISHY, V.
HARTKOORN, R.C., CHANDLER, B., KHOO, S. & BACK, D.J. The interaction between anti-tuberculosis drugs and P-glycoprotein: 676
HARVEY, B.H. *see* BRINK, C.B.
HEATHMAN, M. *see* SKINNER, M.H.
HEIKKILÄ, A. *see* ANTILA, S.
HEINZERLING, H. *see* KAMERLING, I.M.C.
HEKSTER, Y.A. *see* WILTING, I.
HELMS, P.J. *see* KRISHNAMOORTHY, N.
HELMS, P.J. *see* NOVAK, P.
HELMS, P.J. *see* TANAKA, M.
HERING, W. *see* IHMSEN, H.
HERINGS, R.M.C. *see* MANTEL-TEEUWISSE, A.K.
HERINGS, R.M.C. *see* SCHOOFS, M.W.C.J.
HESSELINK, D.A., VAN SCHAIK, R.H.N., SMAK GREGOOR, P.J.H., WEIMAR, W. & VAN GELDER, T. Tacrolimus, but not cyclosporine, dose requirement is correlated with CYP3A5*3 and CYP3A4*1B genotype: 359
HEWITT, S. *see* HUNG, T.-Y.
HEYDARI, A., ROSTAMI-HODJEGAN, A., ROWLAND-YEO, K., LENNARD, M.S. & TUCKER, G.T. Methadone is not a mechanism-based inhibitor of cytochrome P450 2D6: 687
HISHIDA, A. *see* OHASHI, N.
HOFFER, C. *see* KHARASCH, E.D.
HOFMAN, A. *see* MAITLAND-VAN DER ZEE, A.H.
HOFMAN, A. *see* SCHOOFS, M.W.C.J.
HOFMAN, A. *see* VISSER, L.E.
HOIZEY, G. *see* FRANCES, C.
HOLBROOK, A. *see* WILSON, A.M.
HOLGATE, S. *see* NORRIS, V.
HORINAKA, S. *see* MINAMI, J.
HOROWITZ, J.D. *see* DAVIES, B.J.L.
HOROWITZ, J.D. *see* JONES, T.E.
HOUSTON, J.B. *see* ITO, K.
HOUTMAN, P.M. *see* VAN ROON, E.N.
HOVSEPIAN, L. *see* KÅGEDAL, M.
HUA, T.C., PAN, A., CHAN, C., POO, Y.K., SKINNER, M.H., KNADLER, M.P., GONZALES, C.R. & WISE, S.D. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers: 652
HUGHES, A.M. *see* CANTARINI, M.V.
HUITEMA, A.D.R. *see* CROMMENTUYN, K.M.L.
HUITEMA, A.D.R. *see* DE JONGE, M.E.
HULL, R. *see* BOYCE, M.
HUNG, T.-Y. *see* KARUNAJEEWA, H.
HUNG, T.-Y., DAVIS, T.M.E., ILETT, K.F., KARUNAJEEWA, H., HEWITT, S., DENIS, M.B., LIM, C. & SOCHEAT, D. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria: 253
HUSSEIN, Z. *see* PITSIU, M.
HUTCHINSON, M.R., MENELAOU, A., FOSTER, D.J.R., COLLER, J.K. & SOMOGYI, A.A. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes: 287

IHMSEN, H., ALBRECHT, S., HERING, W., SCHÜTTLER, J. & SCHWILDEN, H. Modelling acute tolerance to the EEG effect of two benzodiazepines: 153
ILETT, K.F. *see* BATTY, K.T.
ILETT, K.F. *see* HUNG, T.-Y.
ILETT, K.F. *see* KARUNAJEEWA, H.
INOUE, Y. *see* YASUI-FURUKORI, N.
ISHIMITSU, T. *see* MINAMI, J.
ISMAIL, R. *see* GAN, S.H.
ITO, K., BROWN, H.S. & HOUSTON, J.B. Database analyses for the prediction of *in vivo* drug–drug interactions from *in vitro* data: 473
IVESON, E. *see* RAMBARAN, C.

JACKSON, C.M. *see* LEE, D.K.C.
JACKSON, P.R. *see* KHAWAJA, M.
JACKSON, S.H.D. *see* FORD, G.A.
JACKSON, S.H.D. *see* MANGONI, A.A.
JACKSON, S.H.D., MANGONI, A.A. & BATTY, G.M. Optimization of drug prescribing: 231
JAMES, H.M. *see* DAVIES, B.J.L.
JANSEN, T.L.TH.A. *see* VAN ROON, E.N.
JAUSSAUD, R. *see* TRENQUE, T.
JEWELL, R.C. *see* KUPPENS, I.E.L.M.
JIANG, B. *see* RAMBARAN, C.
JIANG, X., WILLIAMS, K.M., LIAUW, W.S., AMMIT, A.J., ROUFOGALIS, B.D., DUKE, C.C., DAY, R.O. & MCLACHLAN, A.J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects: 592
JOHNSON, P.J. *see* PURKINS, L.
JOHNSON, T.N., ROSTAMI-HODJEGAN, A. & TUCKER, G.T. A comparison of methods to predict drug clearance in neonates, infants and children: 677
JOHNSTON, D., GRIND, M., HAMRÉN, B., BÅÅTHE, S., WOLLBRATT M. & ERIKSSON U.G. Pharmacokinetics of melagatran after oral dosing with ximelagatran in patients with nonvalvular atrial fibrillation: 685
JOHNSTON, N.R. *see* CRUDEN, N.L.
JONES, T.E., MORRIS, R.G. & HOROWITZ, J.D. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state: 263
JOUKHADAR, C. *see* BELLMANN, R.

KÅGEDAL, M., DUVAUCHELLE, T., HOVSEPIAN, L., CHARLESWORTH, B.R., SU, H.-L. & YATES, R. Zolmitriptan demonstrates good pharmacokinetic consistency between and within individuals following intranasal administration: 679
KAJOSAARI, L.I. *see* NIEMI, M.
KALAÇA, S. *see* AKICI, A.
KALRA, L. *see* RAMBARAN, C.
KAMALI, F., KHAN, T.I., KING, B.P., FREARSON, R., KESTEVEN, P., WOOD, P., DALY, A.K. & WYNNE, H. The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements: 668
KAMERLING, I.M.C., VAN HAARST, A.D., BURGGRAAF, J., SCHOEMAKER, R.C., DE KAM, M.L., HEINZERLING, H., COHEN, A.F. & MASCLEE, A.A.M. Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function: 393
KAMMERER, D. *see* STRACHAN, E.M.
KANAMARU, M. *see* OHASHI, N.
KANEKO, S. *see* YASUI-FURUKORI, N.
KARAALP, A. *see* AKICI, A.
KARAKUS, A. *see* KUPPENS, I.E.L.M.
KARLSSON, M.O. *see* KERBUSCH, T.
KARUNAJEEWA, H. *see* HUNG, T.-Y.
KARUNAJEEWA, H., LIM, C., HUNG, T.-Y., ILETT, K.F., DENIS, M.B., SOCHEAT, D. & DAVIS, T.M.E. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin®) in Cambodian children and adults with malaria: 93
KASBERGEN, A.A.H. *see* VISSER, L.E.
KASHANI, L. *see* AKHONDZADEH, S.
KASJE, W.N. *see* DENIG, P.
KASTELEIN, J.J.P. *see* MAITLAND-VAN DER ZEE, A.H.
KEESSEN, M. *see* DE JONGE, M.E.

KELLY, C.A. *see* STRACHAN, E.M.
KENNEDY, J. *see* CHUI, J.
KERBUSCH, T., MILLIGAN, P.A. & KARLSSON, M.O. Assessment of the relative *in vivo* potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic–pharmacodynamic data: 170
KERWIN, R. *see* TAYLOR, D.
KESTEVEN, P. *see* KAMALI, F.
KHAN, T.I. *see* KAMALI, F.
KHARASCH, E.D., HOFFER, C. & WHITTINGTON, D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone: 600
KHAWAJA, M. & JACKSON, P.R. Effect of patient information leaflet on drug preference: 688
KHOO, S. *see* HARTKOORN, R.C.
KING B.P. *see* DALY, A.K.
KING, B.P. *see* KAMALI, F.
KINGMA, J.H. *see* DENEER, V.H.M.
KINIRONS, M.T. & O'MAHONY, M.S. Drug metabolism and ageing: 540
KIRKESSELI, S. *see* NORRIS, V.
KIVIKKO, M. *see* ANTILA, S.
KLEIN, K. *see* COLLER, J.K.
KLUNGEL, O.H. *see* MAITLAND-VAN DER ZEE, A.H.
KLUNGEL, O.H. *see* MANTEL-TEEUWISSE, A.K.
KLUNGEL, O.H. *see* SCHELLEMAN, H.
KNADLER, M.P. *see* HUA, T.C.
KNADLER, M.P. *see* SKINNER, M.H.
KOBAYASHI, N. *see* MINAMI, J.
KOKWARO, G.O. *see* MITHWANI, S.
KONDO, T. *see* YASUI-FURUKORI, N.
KOOPMAN-KROON, C. *see* DE JONGE, M.E.
KOSHIKAWA, S. *see* OHASHI, N.
KOSTRZEWA, M. *see* MARTIN-FACKLAM, M.
KOVARIK, J.M., SCHMOUDER, R., BARILLA, D., WANG, Y. & KRAUS, G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects: 586
KRÄHENBÜHL, S. *see* WENK, M.
KRAMERS, C. *see* MULDER, J.
KRAUS, G. *see* KOVARIK, J.M.
KREBSFAENGER, N. *see* COLLER, J.K.
KRISHNAMOORTHY, N., EKINS-DAUKES, S., SIMPSON, C.R., OSMAN, M., TAYLOR, M., MILNE, R., HELMS, P.J. & MCLAY, J.S. Is the combined oral contraceptive pill associated with a reduction in the risk of asthma in teenage girls? A retrospective study in primary care: 665
KROMHOUT, D. *see* SCHELLEMAN, H.
KUAN, H.-Y. *see* SKINNER, M.H.
KUCHLING, G. *see* BELLMANN, R.
KUIJPERS, T.W. *see* CROMMENTUYN, K.M.L.
KUMANA, C.R. *see* CHEUNG, B.M.Y.
KUMARASWAMY, N. *see* GAN, S.H.
KUPPENS, I.E.L.M., RADEMA, S., ROSING, H., STOKVIS, E., SWART, M., JEWELL, R.C., RUSSO, M., KARAKUS, A., WITTEVEEN, E., BEIJNEN, J.H., VOEST, E.E. & SCHELLENS, J.H.M. A Phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF 120918) in combination with 2.0 mg oral topotecan in cancer patients: 360
KUPPENS, I.E.L.M., VAN MAANEN, M.J., ROSING, H., BOSCH, T.M., FITZPATRICK, A., BEIJNEN, J.H. & SCHELLENS, J.H.M. Oral bioavailability of docetaxel in combination with OC 144–093 (ONT-093): 360
KYRKLUND, C., BACKMAN, J.T., NEUVONEN, M. & NEUVONEN, P.J. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects: 181

LACARELLE, B. *see* SOLAS, C.
LAFEUILLADE, A. *see* SOLAS, C.
LAITILA, J. *see* GRANFORS, M.T.
LARMIE, E.T. *see* GAN, S.H.
LASEUR, M. *see* MOL, P.G.M.
LATRY, P. *see* MARTIN, K.
LAU, C.-P. *see* CHEUNG, B.M.Y.
LAUDER, I.J. *see* CHEUNG, B.M.Y.
LAUGHLIN, M. *see* COURTNEY, R.
LAYTON, G. *see* SOBUE, S.
LEBRUN, S. *see* MALONNE, H.
LECLERC, V. *see* SOBUE, S.
LEE, D.K.C., BATES, C.E. & LIPWORTH, B.J. Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous β_2-adrenoceptor haplotypes at positions 16 and 27: 100
LEE, D.K.C., CURRIE, G.P., HALL, I.P., LIMA, J.J. & LIPWORTH, B.J. The arginine-16 β_2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol: 68
LEE, D.K.C., JACKSON, C.M., SOUTAR, P.C., FARDON, T.C. & LIPWORTH, B.J. Effects of single or combined histamine H_1-receptor and leukotriene $CysLT_1$-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis: 714
LEE, D.K.C. & LIPWORTH, B.J. The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease: 388
LEHTONEN, L. *see* ANTILA, S.
LELORIER, J. *see* QUACH, C.
Lennard, L. *see* CARTWRIGHT, C.S.
LENNARD, M.S. *see* DAVIES, S.J.C.
LENNARD, M.S. *see* HEYDARI, A.
LEPEU, G. *see* SOLAS, C.
LEROUX, B. *see* TRENQUE, T.
LESLIE, S.J., RAHMAN, M.Q., DENVIR, M.A., NEWBY, D.E. & WEBB, D.J. Endothelins and their inhibition in the human skin microcirculation: $ET_{(1-31)}$, a new vasoconstrictor peptide: 720
LEUFKENS, H.G.M. *see* MAITLAND-VAN DER ZEE, A.H.
LEYS, D. *see* DEPLANQUE, D.
LIAUW, W.S. *see* JIANG, X.
LIE-A-HUEN, L. *see* DENEER, V.H.M.
LIGTHELM, R.J. *see* VAN RIEMSDIJK, M.M.
LIM, C. *see* HUNG, T.-Y.
LIM, C. *see* KARUNAJEEWA, H.
LIM, J. *see* COURTNEY, R.
LIMA, J.J. *see* LEE, D.K.C.
LIPWORTH, B.J. *see* LEE, D.K.C.
LOCKTON, J.A. *see* BLAKEY, G.E.
LOKE, Y.K., DERRY, S. & ARONSON, J.K. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone: 616
LOKIEC F. *see* URIEN, S.
LOVE, E.R. *see* PURKINS, L.
LUNDBERG, C.J.F. *see* EDEROTH, P.

MACDONALD, T.M. *see* MORANT, S.V.
MACFADYEN, R.J., GORSKI, J.C., BRATER, D.C. & STRUTHERS, A.D. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study: 622
MACLEOD, M.-J. *see* REID, J.
MAHAGERI, H. *see* AKHONDZADEH, S.
MAHMUD, A. & FEELY, J. Effects of passive smoking on blood pressure and aortic pressure waveform in healthy young adults – influence of gender: 37
MAHMUD, A. & FEELY, J. Vascular effects of amlodipine in essential hypertension: 684
MAHMUD, A. *see* MCNULTY, M.
MAITLAND-VAN DER ZEE, A.H., STRICKER, B.H.CH., KLUNGEL, O.H., KASTELEIN, J.J.P., HOFMAN, A., WITTEMAN, J.C.M., LEUFKENS, H.G.M., VAN DUIJN, C.M. & DE BOER, A. The effectiveness of HMG-COA reductase inhibitors is affected by ACE insertion deletion polymorphism: 361
MAJID, O. *see* MITHWANI, S.
MAJID, O. *see* PITSIU, M.

MALONNE, H., SONET, B., STREEL, B., LEBRUN, S., DE NIET, S., SERENO, A. & VANDERBIST, F. Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol: 270
MANGONI, A.A. *see* FORD, G.A.
MANGONI, A.A. *see* JACKSON, S.H.D.
MANGONI, A.A. & JACKSON, S.H.D. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications: 6
MANTEL-TEEUWISSE, A.K., GOETTSCH, W.G., KLUNGEL, O.H., DE BOER, A. & HERINGS, R.M.C. Determinants of persistence with statin use in daily medical practice: 361
MARSH, K. *see* MITHWANI, S.
MARTIN, K., BÉGAUD, B., LATRY, P., MIREMONT-SALAMÉ, G., FOURRIER, A. & MOORE, N. Differences between clinical trials and postmarketing use: 86
MARTIN, P. *see* MARTIN-FACKLAM, M.
MARTIN, P.D. *see* SIMONSON, S.G.
MARTIN-FACKLAM, M. *see* FRÖHLICH, M.
MARTIN-FACKLAM, M., KOSTRZEWA, M., MARTIN, P. & HAEFELI, W.E. Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality. An intervention study on pages about sildenafil: 80
MAS, J.-L. *see* DEPLANQUE, D.
MASCLEE, A.A.M. *see* KAMERLING, I.M.C.
MATHÔT, R.A.A. *see* CROMMENTUYN, K.M.L.
MATHÔT, R.A.A. *see* DE JONGE, M.E.
MATSUOKA, H. *see* MINAMI, J.
MAXWELL, S.J.M. *see* PAYNE, R.A.
MAYER, B.X. *see* BELLMANN, R.
MCCAUGHAN, G. *see* ZAHIR, H.
MCGEECHAN, K. *see* ROUGHEAD, E.E.
MCLACHLAN, A.J. *see* BLAIR, E.Y.L.
MCLACHLAN, A.J. *see* JIANG, X.
MCLACHLAN, A.J. *see* SLAVIERO, K.A.
MCLACHLAN, A.J. *see* ZAHIR, H.
MCLAY, J.S. *see* KRISHNAMOORTHY, N.
MCLAY, J.S. *see* MCLNTYRE, C.
MCLAY, J.S. *see* NOVAK, P.
MCLAY, J.S. *see* TANAKA, M.
MCLNTYRE, C. & MCLAY, J.S. The relationship between self reported compliance with simvastatin and attainment of target lipid concentrations. A prospective study: 682
MCMAHON, A.D. *see* MORANT, S.V.
MCNULTY, M., MAHMUD, A. & FEELY, J. Matrix metalloproteinase-1, collagen turnover and increased aortic pulse wave velocity: 681
MENELAOU, A. *see* HUTCHINSON, M.R.
MERKUS, F.W.H.M. *see* MERKUS, P.
MERKUS, P., GUCHELAAR, H.J., BOSCH, D.A. & MERKUS, F.W.H.M. Nasal drug delivery to the cerebrospinal fluid: transport of a hydrophilic drug: 362
MEULENDIJKS, C. *see* MULDER, J.
MIHARA, K. *see* YASUI-FURUKORI, N.
MILLART, H. *see* FRANCES, C.
MILLART, H. *see* TRENQUE, T.
MILLET, S. *see* NORRIS, V.
MILLIGAN, P.A. *see* KERBUSCH, T.
MILNE, R. *see* KRISHNAMOORTHY, N.
MILNE, R. *see* NOVAK, P.
MINAMI, J., NUMABE, A., ANDOH, N., KOBAYASHI, N., HORINAKA, S., ISHIMITSU, T. & MATSUOKA, H. Comparison of once-daily nifedipine controlled-release with twice-daily nifedipine retard in the treatment of essential hypertension: 632
MINAR, E. *see* BELLMANN, R.
MIREMONT-SALAMÉ, G. *see* MARTIN, K.
MITCHELL, A. *see* WENZEL, R.R.
MITCHELL, P.D. *see* SIMONSON, S.G.
MITHWANI, S., AARONS, L., KOKWARO, G.O., MAJID, O., MUCHOHI, S., EDWARDS, G., MOHAMED, S., MARSH, K. & WATKINS, W. Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria: 146
MOHAMED, S. *see* MITHWANI, S.
MOHAMMADI, M.R. *see* AKHONDZADEH, S.
MOKHTARI, M. *see* SOLAS, C.
MOL, P.G.M., DENIG, P., NANNAN PANDAY, P.V., GANS, R.O.B., DEGENER, J.E., LASEUR, M. & HAAIJER-RUSKAMP, F.M. When are antimicrobial treatment guidelines not followed?: 362
MOL, P.G.M., NANNAN PANDAY, P.V., DEGENER, J.E., VAN DER WERF, T.S., HAAIJER-RUSKAMP, F.M. & GANS, R.O.B. Academic fluoroquinolone prescribing, resistance and impact of guidelines: 363
MONSTER, T.B.M. *see* ATTHOBARI, J.
MOOLENAAR, M. *see* WILTING, I.
MOORE, N. *see* MARTIN, K.
MOORE, P.K. *see* RANG, H.P.
MORANT, S.V., MCMAHON, A.D., CLELAND, J.G.F., DAVEY, P.G. & MACDONALD, T.M. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity: 188
MOREAU, J. *see* SOLAS, C.
MORRIS, R.G. *see* DAVIES, B.J.L.
MORRIS, R.G. *see* JONES, T.E.
MORTIER, E.P. *see* STRUYS, M.M.R.F.
MOTTRAM, D.R. *see* CHESTER, N.
MOURAD, L. *see* VAN ROON, E.N.
MOVIG, K.L.L. *see* WILTING, I.
MOZAYANI, E.A. & RAYMON, L.P. Handbook of Drug Interactions. A Clinical and Forensic Guide: 818
MÜLLER, M. *see* BELLMANN, R.
MÜRDTER, T.E. *see* COLLER, J.K.
MUCHOHI, S. *see* MITHWANI, S.
MULDER, J., MEULENDIJKS, C., NEEF, C., NATSCH, S. & KRAMERS, C. Reliability of reported ingestion in paracetamol overdose: 364
MUNAFO, A. *see* GOGGIN, T.

NACAK, M. *see* AYNACIOGLU, A.S.
NAGASHIMA, S. *see* OHASHI, N.
NAISBITT, D.J. *see* FARRELL, J.
NAISBITT, D.J. *see* WU, Y.
NAISBITT, D.J., FARRELL, J., CHAMBERLAIN, P.J., PARK, B.K. & PIRMOHAMED, M. Characterization of T-cell responses in phenindione hypersensitivity: 675
NAISBITT, D.J., WU, Y., FARRELL, J., O'NEILL, P.M., PIRMOHAMED, M. & PARK, B.K. T-cell recognition of carbamazepine and carbamazepine metabolites: 669
NAKAGAMI, T. *see* YASUI-FURUKORI, N.
NAND, R.A. *see* ZAHIR, H.
NANNAN PANDAY, P.V. *see* MOL, P.G.M.
NATSCH, S. *see* MULDER, J.
NEEF, C. *see* MULDER, J.
NENTWICH, H. *see* BOYCE, M.
NEUHAUS, P. *see* COLLER, J.K.
NEUVONEN, M. *see* KYRKLUND, C.
NEUVONEN, M. *see* NIEMI, M.
NEUVONEN, P.J. *see* GRANFORS, M.T.
NEUVONEN, P.J. *see* KYRKLUND, C.
NEUVONEN, P.J. *see* NIEMI, M.
NEWBY, D.E. *see* CRUDEN, N.L.
NEWBY, D.E. *see* LESLIE, S.J.
NGUYEN, Q.T.X. *see* GOGGIN, T.
NIEMAN, F.H.M. *see* REIJNTJENS, S.
NIEMI, M., KAJOSAARI, L.I., NEUVONEN, M., BACKMAN, J.T. & NEUVONEN, P.J. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects: 441
NISHIKI, K. *see* TSURUOKA, S.
NORDSTRÖM, C.-H. *see* EDEROTH, P.
NORRIS, V. *see* BOYCE, M.
NORRIS, V., CHOONG, L., TRAN, D., CORDEN, Z., BOYCE, M., ARSHAD, S., HOLGATE, S., O'CONNOR, B., MILLET, S. & KIRKESSELI, S. A placebo controlled, double-blind, crossover study of 8 days treatment with IVL745, a VLA-4 antagonist, in mild atopic asthma: 676

NORWOOD, P. *see* BLAKEY, G.E.
NOVAK, P., EKINS-DAUKES, S., SIMPSON, C.R., TAYLOR, M., MILNE, R., HELMS, P.J. & MCLAY, J.S. Acute prescribing in general practice to children on longterm antiepiletic therapy. The potential for acute drug-drug interactions. A retrospective observational study: 666
NÜSSLER, A. *see* COLLER, J.K.
NUMABE, A. *see* MINAMI, J.

ÖZDEMIR, M., AKTAN, Y., ROSTAMI-HODJEGAN, A., CREWE, H.K. & TUCKER, G.T. Assessment of CYP2D6 *in vivo* activity: relative sensitivity of urinary metabolic ratios of debrisoquine (DB), dextromethorphan (DM) and metoprolol (MP) to urine pH: 686
O'BRIEN, L. *see* SKINNER, M.H.
O'CONNOR, B. *see* NORRIS, V.
O'CONNOR, H. *see* BENNETT, K.
O'GRADY, J. *see* GRIFFIN, J.P.
O'GRADY, J. *see* SINZINGER, H.
O'MAHONY, M.S. *see* KINIRONS, M.T.
O'MAHONY, M.S. *see* ROUTLEDGE, P.A.
O'MORAIN, C. *see* BENNETT, K.
O'NEILL, P.M. *see* NAISBITT, D.J.
ODUBANJO, E., BENNETT, K. & FEELY, J. Is the quality of prescribing in the elderly related to socio-economic status?: 665
ODUBANJO, E., BENNETT, K. & FEELY, J. Prescribing of antidepressants in patients with recent onset and existing ischaemic heart disease in general practice: 680
ODUBANJO, E., BENNETT, K. & FEELY, J. Variation in the prescribing of antidepressants, anxiolytics, hypnotics and sedatives in general practice: 679
OHASHI, N., UEMATSU, T., NAGASHIMA, S., KANAMARU, M., TOGAWA, A., HISHIDA, A., UCHIDA, E., AKIZAWA, T. & KOSHIKAWA, S. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis: 726
OKTAY, Ş. *see* AKICI, A.
OLIVER, D.W. *see* BRINK, C.B.
OLIVER, J.J. *see* ATTINÀ, T.
OLIVER, J.J., BEUDEKER, Q.H., CATE, T.T., BOWLER, A. & WEBB, D.J. The dose-response relationship of sublingual GTN to brachial artery diameter and change in augmentation index: 673
OOSTERINK, B.J. *see* DUMONT, G.J.H.
OOSTVOGEL, P.M. *see* BARTELINK, I.H.
OSMAN, M. *see* KRISHNAMOORTHY, N.
OVERBOSCH, D. *see* VAN RIEMSDIJK, M.M.
OVERDIEK, J.W.P.M. *see* BARTELINK, I.H.
OWEN, R.J. *see* BJARNASON, I.T.
OXLADE, N. *see* BJARNASON, I.T.

PALTANSING, S. *see* DUMONT, G.J.H.
PAN, A. *see* HUA, T.C.
PARK, B.K. *see* FARRELL, J.
PARK, B.K. *see* NAISBITT, D.J.
PARK, B.K. *see* WU, Y.
PARNETTI, L. *see* DEPLANQUE, D.
PATON, C. *see* TAYLOR, D.
PAYNE, R.A., SYMEONIDE, C.N., MAXWELL, S.J.M. & WEBB, D.J. Pulse transit time measured from the ECG as a marker of beat-to-beat blood pressure: 691
PENNING-VAN BEEST, F.J.A. *see* VISSER, L.E.
PENTIKÄINEN, P.J. *see* ANTILA, S.
PERRETT, J. *see* BLAKEY, G.E.
PERSKY, A.M., BERRY, N.S., POLLACK, G.M. & BROUWER, K.L.R. Modelling the cardiovascular effects of ephedrine: 552
PETIT, N. *see* SOLAS, C.
PHILIPP, T. *see* WENZEL, R.R.
PIERCE, R. *see* DISHY, V.
PINON, J.-M. *see* TRENQUE, T.
PIRMOHAMED, M. *see* FARRELL, J.
PIRMOHAMED, M. *see* NAISBITT, D.J.
PIRMOHAMED, M. *see* WU, Y.
PITSIU, M., HUSSEIN, Z., MAJID, O., AARONS, L., DE LONGUEVILLE, M. & STOCKIS, A. Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years: 402
PLUME, J. *see* BLAKEY, G.E.
POHJANJOUSI, P. *see* ANTILA, S.
POIZOT-MARTIN, I. *see* SOLAS, C.
POLLACK, G.M. *see* PERSKY, A.M.
POLS, H.A.P. *see* SCHOOFS, M.W.C.J.
POO, Y.K. *see* HUA, T.C.
PORTNER, R., WILSON, C., YEO, K.R. & YEO, W.W. In-patient initiation of warfarin treatment: an audit: 668
POSNER, J. *see* CALDER, N.
POUCHER, S.M. *see* GREENHAFF, P.L.
POWELL, M. *see* CHESTER, N.
PRASAD, H.C. *see* DISHY, V.
PRATT, P. *see* DAVIES, S.J.C.
PRICE, A.B. *see* BJARNASON, I.T.
PROOST, J.H. *see* DENEER, V.H.M.
PURKINS, L., LOVE, E.R., EVE, M.D., WOOLDRIDGE, C.L., COWAN, C., SMART, T.S., JOHNSON, P.J. & RAPEPORT, W.G. The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit: 199
QUACH, C., COLLET, J.-P. & LELORIER, J. Acute otitis media in children: a retrospective analysis of physician prescribing patterns: 500
QUASIM, A. *see* BENNETT, K.
QUEREUX, C. *see* TRENQUE, T.

RADEMA, S. *see* KUPPENS, I.E.L.M.
RADWANSKI, E. *see* COURTNEY, R.
RAHMAN, M.Q. *see* LESLIE, S.J.
RALPH, L.D., THOMSON, A.H., DOBBS, N.A. & TWELVES, C. Maximum *a posteriori* Bayesian estimation of epirubicin clearance by limited sampling: 764
RAMBARAN, C., IVESON, E., WILLIAMS, I.L., JIANG, B., CHOWIENCZYK, P.J., RITTER, J.M., SHAH, A.M., FORRESTER, T. & KALRA, L. Relation between β_2-adrenoceptor responsiveness assessed by pulse wave analysis and flow mediated dilation: 675
RANG, H.P., DALE, M.M. RITTER, J.M. & MOORE, P.K. Pharmacology, 5th edn: 112
RAPEPORT, W.G. *see* PURKINS, L.
RAVAUX, I. *see* SOLAS, C.
RAYMON, L.P. *see* MOZAYANI, E.A.
RÉMY, G. *see* TRENQUE, T.
REDDY, S. *see* SKINNER, M.H.
REID, J., MACLEOD, M.-J. & WILLIAMS, D. Timing of aspirin use in acute stroke and use of secondary prevention: stroke unit *vs* medical unit: 673
REIJNTJENS, S., GUILLAUME, C., STOLK, L., DEGRAEUWE, P.L.J., NIEMAN, F.H.M. & DE BOER, A. Amoxicillin pharmacokinetics in (pre)term neonates: 364
REILLY, T. *see* CHESTER, N.
REITH, D. *see* CHUI, J.
REMON, J.P. *see* VAN DEN ABEELE, W.M.
REUCK, J.D. *see* DEPLANQUE, D.
RITTER, J.M. *see* BRETT, S.E.; RAMBARAN, C.
RITTER, J.M. *see* RANG, H.P.
RIVORY, L.P. *see* BLAIR, E.Y.L.
RIVORY, L.P. *see* SLAVIERO, K.A.
ROBERTS, P.A. *see* GREENHAFF, P.L.
RODENHUIS, S. *see* DE JONGE, M.E.
RONGEN, MD, PHD, G.A. *see* VAN GINNEKEN, MD, E.E.M.
ROOTS, I. *see* AYNACIOGLU, A.S.
ROSING, H. *see* DE JONGE, M.E.
ROSING, H. *see* KUPPENS, I.E.L.M.
ROSTAMI-HODJEGAN, A. *see* HEYDARI, A.
ROSTAMI-HODJEGAN, A. *see* JOHNSON, T.N.
ROSTAMI-HODJEGAN, A. *see* ÖZDEMIR, M.
ROSTAMI-HODJEGAN, A. *see* ROWLAND YEO, K.

ROUFOGALIS, B.D. *see* JIANG, X.
ROUGHEAD, E.E., MCGEECHAN, K. & SAYER, G.P. Bisphosphonate use and subsequent prescription of acid suppressants: 813
ROUTLEDGE, P.A., O'MAHONY, M.S. & WOODHOUSE, K.W. Adverse drug reactions in elderly patients: 121
ROWLAND YEO, K. *see* BECK, C.R.
ROWLAND YEO, K., ROSTAMI-HODJEGAN, A. & TUCKER, G.T. Abundance of cytochromes P450 in human liver: a meta-analysis: 687
ROWLAND-YEO, K. *see* HEYDARI, A.
RUSSELL, M. *see* BLAKEY, G.E.
RUSSO, M. *see* KUPPENS, I.E.L.M.

SALLUSTIO, B.C. *see* DAVIES, B.J.L.
SASTRE TORAÑO, J. *see* VAN KAN, H.J.M.
SAVAGE, C.M. *see* CARTWRIGHT, C.S.
SAYER, G.P. *see* ROUGHEAD, E.E.
SCHÄFERS, R.F. *see* WENZEL, R.R.
SCHAARS, C.F. *see* DENIG, P.
SCHELLEMAN, H., KLUNGEL, O.H., VERSCHUREN, W.M.M., DE BOER, A., STRICKER, B.H.CH. & KROMHOUT, D. Prevalence and determinants of undertreatment of hypertension in the Netherlands: 365
SCHELLENS, J.H.M. *see* DE JONGE, M.E.
SCHELLENS, J.H.M. *see* KUPPENS, I.E.L.M.
SCHERPBIER, H.J. *see* CROMMENTUYN, K.M.L.
SCHMIDT, R. *see* DEPLANQUE, D.
SCHMOUDER, R. *see* KOVARIK, J.M.
SCHNECK, D.W. *see* SIMONSON, S.G.
SCHOEMAKER, R. *see* DUMONT, G.J.H.
SCHOEMAKER, R.C. *see* KAMERLING, I.M.C.
SCHOOFS, M.W.C.J., VAN DER KLIFT, M., HOFMAN, A., DE LAET, C.E.D.H., HERINGS, R.M.C., POLS, H.A.P. & STRICKER, B.H.CH. Thiazide diuretics and the risk of hip fracture: 365
SCHÜTTLER, J. *see* IHMSEN, H.
SCHWILDEN, H. *see* IHMSEN, H.
SCIBERRAS, D. *see* CALDER, N.
SEGER, M.E. *see* SKINNER, M.H.
SERENO, A. *see* MALONNE, H.
SHAH, A.M. *see* RAMBARAN, C.
SIFFERT, W. *see* WENZEL, R.R.
SIMON, N. *see* TRENQUE, T.
SIMONSON, S.G., MARTIN, P.D., WARWICK, M.J., MITCHELL, P.D. & SCHNECK, D.W. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive: 279
SIMPSON, C.R. *see* KRISHNAMOORTHY, N.
SIMPSON, C.R. *see* NOVAK, P.
SIMPSON, C.R., HANNAFORD, P.J. & WILLIAMS, D. Gender and age differences in the secondary prevention of coronary heart disease in Scotland: a cross sectional study using primary care data: 672
SINZINGER, H. & O'GRADY, J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems: 525
SKERJANEC, A. *see* SKINNER, M.H.
SKINNER, M.H. *see* HUA, T.C.
SKINNER, M.H., KUAN, H.-Y., SKERJANEC, A., SEGER, M.E., HEATHMAN, M., O'BRIEN, L., REDDY, S. & KNADLER, M.P. Effect of age on the pharmacokinetics of duloxetine in women: 54
SLAVIERO, K.A., CLARKE, S.J., MCLACHLAN, A.J., BLAIR, E.Y.L. & RIVORY, L.P. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer: 44
SMAK GREGOOR, P.J.H. *see* HESSELINK, D.A.
SMART, T.S. *see* PURKINS, L.
SMITS, MD, PHD, P. *see* VAN GINNEKEN, MD, E.E.M.
SOBUE, S., TAN, K., LAYTON, G., LECLERC, V. & WEIL, A. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole: 773
SOCHEAT, D. *see* HUNG, T.-Y.
SOCHEAT, D. *see* KARUNAJEEWA, H.
SOFOWORA, G. *see* DISHY, V.
SOLAS, C., POIZOT-MARTIN, I., DROGOUL, M.-P., RAVAUX, I., DHIVER, C., LAFEUILLADE, A., ALLEGRE, T., MOKHTARI, M., MOREAU, J., LEPEU, G., PETIT, N., DURAND, A. & LACARELLE, B. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor: 436
SOMOGYI, A.A. *see* DAVIES, B.J.L.
SOMOGYI, A.A. *see* FOSTER, D.J.R.
SOMOGYI, A.A. *see* HUTCHINSON, M.R.
SONET, B. *see* MALONNE, H.
SOUTAR, P.C. *see* LEE, D.K.C.
SPIEKSMA, M. *see* VAN KAN, H.J.M.
STEIN, C.M. *see* DISHY, V.
STOCKIS, A. *see* PITSIU, M.
STOKVIS, E. *see* KUPPENS, I.E.L.M.
STOLK, L. *see* REIJNTJENS, S.
STRACHAN, E.M., KAMMERER, D., KELLY, C.A. & BATEMAN, D.N. Electrocardiograph and haemodynamic changes in thioridazine and chlorpromazine overdose: 678
STRACK VAN SCHIJNDEL, R.M.J. *see* SWART, E.L.
STREEL, B. *see* MALONNE, H.
STRICKER, B.H. *see* VAN RIEMSDIJK, M.M.
STRICKER, B.H. *see* VISSER, L.E.
STRICKER, B.H.CH. *see* MAITLAND-VAN DER ZEE, A.H.
STRICKER, B.H.CH. *see* SCHELLEMAN, H.
STRICKER, B.H.CH. *see* SCHOOFS, M.W.C.J.
STRICKER, B.H.CH. *see* VISSER, L.E.
STROWITZKI, T. *see* FRÖHLICH, M.
STRUTHERS, A.D. *see* MACFADYEN, R.J.
STRUYS, M.M.R.F., VEREECKE, H.E.M. & MORTIER, E.P. Electro-encephalographic surrogate measures fail to describe the pharmacodynamic interaction between ketamine and propofol: 366
STURKENBOOM, M.C.J.M. *see* GREVING, J.P.
STURKENBOOM, M.C.J.M. *see* VAN RIEMSDIJK, M.M.
STUURMAN, A. *see* DENEER, V.H.M.
SU, H.-L. *see* KÅGEDAL, M.
SUGIMOTO, K. *see* TSURUOKA, S.
SUZUKI, A. *see* YASUI-FURUKORI, N.
SWART, E.L., ZUIDEVELD, K.P., DE JONGH, J., DANHOF, M., THIJS, L.G. & STRACK VAN SCHIJNDEL, R.M.J. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients: 135
SWART, M. *see* KUPPENS, I.E.L.M.
SYMEONIDE, C.N. *see* PAYNE, R.A.

TAKAHATA, T. *see* YASUI-FURUKORI, N.
TAN, K. *see* SOBUE, S.
TANAKA, M., EKINS-DAUKES, S., HELMS, P.J. & MCLAY, J.S. Off label drug use in children. A prospective questionnaire assessment of attitudes amongst scottish hospital based paediatricians: 677
TATEISHI, T. *see* YASUI-FURUKORI, N.
TAYLOR, D., PATON, C. & KERWIN, R. The Maudsley 2003 Prescribing Guidelines, 7th edition: 661
TAYLOR, G.R. *see* DOOLEY, M.J.
TAYLOR, M. *see* KRISHNAMOORTHY, N.
TAYLOR, M. *see* NOVAK, P.
TAYLOR, S. Quinine intoxications: a continuing problem: 817
TEELING, M. *see* USHER, C.
TEELING, M., BENNETT, K. & FEELY, J. Have clinical guidelines on use of statins been implemented in primary care?: 671
TEELING, M., BENNETT, K. & FEELY, J. Have COX-2 inhibitors influenced the

co-prescription of anti-ulcer drugs with NSAIDs?: 337
TEHRANIDOOST, M. *see* AKHONDZADEH, S.
THABANE, L. *see* WILSON, A.M.
THIJS, L.G. *see* SWART, E.L.
THOMSON, A.H. *see* RALPH, L.D.
THORNTON, O. *see* BENNETT, K.
TIBBOEL, D. *see* ALLEGAERT, K.
TIMMONS, J.A. *see* GREENHAFF, P.L.
TOBI, H. *see* VAN ROON, E.N.
TODESCO, L. *see* WENK, M.
TOGAWA, A. *see* OHASHI, N.
TORDOFF, J. *see* CHUI, J.
TRAN, D. *see* NORRIS, V.
TRENQUE, T. *see* FRANCES, C.
TRENQUE, T., SIMON, N., VILLENA, I., CHEMLA, C., QUEREUX, C., LEROUX, B., JAUSSAUD, R., RÉMY, G., DUPOUY, D., MILLART, H., PINON, J.-M. & URIEN, S. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis: 735
TSURUOKA, S., WAKAUMI, M., NISHIKI, K., ARAKI, N., HARADA, K., SUGIMOTO, K. & FUJIMURA, A. Subclinical alteration of taste sensitivity induced by candesartan in healthy subjects: 807
TUCKER, G.T. *see* HEYDARI, A.
TUCKER, G.T. *see* JOHNSON, T.N.
TUCKER, G.T. *see* ÖZDEMIR, M.
TUCKER, G.T. *see* ROWLAND YEO, K.
TULEN, J.H.M. *see* VAN RIEMSDIJK, M.M.
TUNBLAD, K. *see* EDEROTH, P.
TURNER, C. *see* BRETT, S.E.
TWELVES, C. *see* RALPH, L.D.

UCHIDA, E. *see* FUKAZAWA, I.
UCHIDA, E. *see* OHASHI, N.
UCHIDA, N. *see* FUKAZAWA, I.
UEMATSU, T. *see* OHASHI, N.
UGURLU, M.Ü. *see* AKICI, A.
UNGERSTEDT, U. *see* EDEROTH, P.
URIEN, S. & LOKIEC F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients: 756
URIEN, S. *see* TRENQUE, T.
USHER, C., BENNETT, K. & FEELY, J. Adherence to treatment in older people in primary care – a nested case control study: 680
USHER, C., TEELING, M., BENNETT, K. & FEELY, J. Effect of the Women's Health Initiative trial on hormone replacement therapy prescribing: 667
UYTDEHAAG, G.M.M. *see* DENEER, V.H.M.

VAN ASSELT, G.J. *see* BARTELINK, I.H.
VAN BORTEL, L.M. *see* VAN DEN ABEELE, W.M.
VAN BURGEL, N. *see* DUMONT, G.J.H.
VAN DEN ABEELE, W.M., DE BRABANDER, C., VERVAET, C., REMON, J.P. & VAN BORTEL, L.M. Bioavailability of ibuprofen from hot-melt extruded mini-matrices: 366
VAN DEN BERG, L.H. *see* VAN KAN, H.J.M.
VAN DEN BONGARD, H.J.G.D. *see* DE JONGE, M.E.
VAN DEN BROEK, P. *see* VAN GINNEKEN, MD, E.E.M.
VAN DER KLIFT, M. *see* SCHOOFS, M.W.C.J.
VAN DER LINDEN, M. *see* DUMONT, G.J.H.
VAN DER VEEN, W.J. *see* GREVING, J.P.
VAN DER WERF, T.S. *see* MOL, P.G.M.
VAN DUIJN, C.M. *see* MAITLAND-VAN DER ZEE, A.H.
VAN DUIJN, C.M. *see* VISSER, L.E.
VAN GELDER, T. *see* HESSELINK, D.A.
VAN GERVEN, J.M.A. *see* DUMONT, G.J.H.
VAN GERVEN, J.M.A. *see* FRANSON, K.L.
VAN GIERSBERGEN, P.L.M. *see* DINGEMANSE, J.
VAN GINNEKEN, MD, E.E.M., VAN DEN BROEK, P., SMITS, MD, PHD, P. & RONGEN, MD, PHD, G.A. Human adenosine kinetics measured by microdialysis: 367
VAN HAARST, A.D. *see* KAMERLING, I.M.C.
VAN HEESWIJK, R.P.G. *see* CROMMENTUYN, K.M.L.
VAN HEMEL, N.M. *see* DENEER, V.H.M.
VAN KAN, H.J.M., GROENEVELD, G.J., SASTRE TORAÑO, J., SPIEKSMA, M., VAN DEN BERG, L.H. & GUCHELAAR, H.J. Correlation between riluzole clearance and CYP1A2 activity in patients with amyotrophic lateral sclerosis: 367
VAN MAANEN, M.J. *see* KUPPENS, I.E.L.M.
VAN MAANEN, R. *see* DE JONGE, M.E.
VAN RIEMSDIJK, M.M., STURKENBOOM, M.C.J.M., DITTERS, J.M., TULEN, J.H.M., LIGTHELM, R.J., OVERBOSCH, D. & STRICKER, B.H. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine: 506
VAN ROON, E.N., JANSEN, T.L.TH.A., MOURAD, L., HOUTMAN, P.M., BRUYN, G.A.W., GRIEP, E.N., WILFFERT, B., TOBI, H. & BROUWERS, J.R.B.J. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice: 790
VAN SCHAIK, R.H.N. *see* HESSELINK, D.A.
VAN SCHAIK, R.H.N. *see* VISSER, L.E.
VAN VLIET, M. *see* VISSER, L.E.
VAN ZANDWIJK, N. *see* DE JONGE, M.E.
VANDERBIST, F. *see* MALONNE, H.
VANMOLKOT, F.H.M. & DE HOON, J.N.J.M. Calcitonin gene-related peptide-induced vasodilation in the human forearm: inhibition by the CGRP-receptor antagonist $CGRP_{8-37}$: 368
VENTER, D.P. *see* BRINK, C.B.
VERBESSELT, R. *see* ALLEGAERT, K.
VEREECKE, H.E.M. *see* STRUYS, M.M.R.F.
VERSCHUREN, W.M.M. *see* SCHELLEMAN, H.
VERVAET, C. *see* VAN DEN ABEELE, W.M.
VILLENA, I. *see* TRENQUE, T.
VISSER, L.E., PENNING-VAN BEEST, F.J.A., WILSON, J.H.P., VULTO, A.G., KASBERGEN, A.A.H., DE SMET, P.A.G.M., HOFMAN, A. & STRICKER, B.H. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon: 522
VISSER, L.E., VAN VLIET, M., VAN SCHAIK, R.H.N., KASBERGEN, A.A.H., DE SMET, P.A.G.M., VULTO, A.G., HOFMAN, A., VAN DUIJN, C.M. & STRICKER, B.H.CH. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon: 369
VOEST, E.E. *see* KUPPENS, I.E.L.M.
VON WOLFF, M. *see* FRÖHLICH, M.
VULTO, A.G. *see* VISSER, L.E.

WAKAUMI, M. *see* TSURUOKA, S.
WALTER-SACK, I. *see* FRÖHLICH, M.
WAN ADNAN, W.A. *see* GAN, S.H.
WANG, Y. *see* KOVARIK, J.M.
WARRINGTON, S. *see* BOYCE, M.
WARWICK, M.J. *see* SIMONSON, S.G.
WATKINS, C.L. *see* CANTARINI, M.V.
WATKINS, W. *see* MITHWANI, S.
WEBB, D.J. *see* ATTINÀ, T.
WEBB, D.J. *see* CARLSON, R.V.
WEBB, D.J. *see* CRUDEN, N.L.
WEBB, D.J. *see* LESLIE, S.J.
WEBB, D.J. *see* OLIVER, J.J.
WEBB. D.J. *see* PAYNE, R.A.
WEIL, A. *see* SOBUE, S.
WEIMAR, W. *see* HESSELINK, D.A.
WEISS, J. & HAEFELI, W.E. Genotyping of the A6986G polymorphism of *CYP3A5*: 663
WEISS, J. *see* FRÖHLICH, M.
WELLER, C. *see* BJARNASON, I.T.
WENK, M., TODESCO, L. & KRÄHENBÜHL, S. Effect of St John's

Wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females: 495
WENZEL, R.R., MITCHELL, A., SIFFERT, W., BÜHRMANN, S., PHILIPP, T. & SCHÄFERS, R.F. The I_1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress: 545
WEXLER, D. *see* COURTNEY, R.
WHITE, J.M. *see* FOSTER, D.J.R.
WHITTINGTON, D. *see* KHARASCH, E.D.
WILFFERT, B. *see* VAN ROON, E.N.
WILKINS, M.R. Experimental Therapeutics: 354
WILLIAMS, D. *see* REID, J.; SIMPSON, C.R.
WILLIAMS, D., BENNETT, K. & FEELY, J. Increased prescribing for osteoporosis following exposure to glucocorticoids particularly inhaled steroids: 669
WILLIAMS, I.L. *see* RAMBARAN, C.
WILLIAMS, K.M. *see* JIANG, X.
WILSON, A.M., THABANE, L. & HOLBROOK, A. Application of data mining techniques in pharmacovigilance: 127
WILSON, C. *see* PORTNER, R.
WILSON, J.H.P. *see* VISSER, L.E.
WILTING, I., MOOLENAAR, M., MOVIG, K.L.L., HEKSTER, Y.A., BROUWERS, J.R.B.J. & EGBERTS, A.C.G. Determinants of elevations of lithium serum levels into the toxic range: 369
WISE, S.D. *see* HUA, T.C.
WITHEROW, F.N. *see* CRUDEN, N.L.
WITTEMAN, J.C.M. *see* MAITLAND-VAN DER ZEE, A.H.
WITTEVEEN, E. *see* KUPPENS, I.E.L.M.
WOLBOLD, R. *see* COLLER, J.K.
WOLLBRATT M. *see* JOHNSTON, D.
WOOD, A.J.J. *see* DISHY, V.
WOOD, P. *see* KAMALI, F.
WOODHOUSE, K.W. *see* ROUTLEDGE, P.A.
WOOLDRIDGE, C.L. *see* PURKINS, L.
WORTHLEY, M.I., CORTI, R. & WORTHLEY, S.G. Vasopeptidase inhibitors: will they have a role in clinical practice?: 27
WORTHLEY, S.G. *see* WORTHLEY, M.I.
WU, Y. *see* NAISBITT, D.J.
WU, Y., FARRELL, J., PIRMOHAMED, M., PARK, B.K. & NAISBITT, D.J. Drug-specific proliferation of lymphocytes from patients hypersensitive to carbamazepine and oxcarbazepine: cross-reactivity and possible clinical implications: 683
WYNNE, H. *see* KAMALI, F.
YASUHARA, H. *see* FUKAZAWA, I.
YASUI-FURUKORI, N., MIHARA, K., TAKAHATA, T., SUZUKI, A., NAKAGAMI, T., DE VRIES, R., TATEISHI, T., KONDO, T. & KANEKO S. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes: 569
YASUI-FURUKORI, N., TAKAHATA, T., NAKAGAMI, T., YOSHIYA, G., INOUE, Y., KANEKO, S. & TATEISHI, T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes: 487
YATES, R. *see* KÅGEDAL, M.
YEO, K.R. *see* PORTNER, R.
YEO, W.W. *see* BECK, C.R.
YEO, W.W. *see* PORTNER, R.
YOSHIYA, G. *see* YASUI-FURUKORI, N.

ZAHIR, H., MCCAUGHAN, G., GLEESON, M., NAND, R.A. & MCLACHLAN, A.J. Factors affecting variability in distribution of tacrolimus in liver transplant recipients: 298
ZANGER, U.M. *see* COLLER, J.K.
ZEITLINGER, M. *see* BELLMANN, R.
ZUIDEVELD, K.P. *see* SWART, E.L.
ZULMI, W. *see* GAN, S.H.

DOI:10.1111/j.1365-2125.2004.02167.x

SUBJECT INDEX

This index was compiled from the keywords

α-OH-tam, 105
ACE inhibitors, 27
acenocoumarol, 522
acute otitis media, 500
adenosine monophosphate, 714
adenosine monophosphate PC_{20}, 68
adverse drug events, 127
adverse drug reactions, 121, 813
adverse effects, 188, 616
adverse events, 513, 552
adverse gastrointestinal events, 813
adverse reactions, 506, 807
age, 569
ageing, 6, 15, 121, 231
AHPPI, 76
aldosterone, 622
alveolar absorption, 388
Amiodarone, 616
angiotensin-II receptor blockers, 807
anomer, 529
antagonist, 393
antagonists, 720
antibiotic, 500
anticancer drugs, 756
anticoagulants, 592
antihistamine, 402
anti-peptic ulcer drugs, 337
artemether, 146
arterial stiffness, 37
aspirin, 188
assessment, 162
asthma, 100, 213
atorvastatin, 448
atrial fibrillation, 798
augmentation index, 37
autonomic nervous function, 632

β_2-adrenoceptor haplotype, 100
β_2-adrenoceptor polymorphism, 68, 100
benzodiazepines, 153
biological availability, 218
bisphosphonates, 813
blood distribution, 298
blood pressure, 37, 632
blood pressure lowering drug, 328
blood–brain barrier, 427, 600
body mass index, 506
brachial artery, 209
brain injury, 427
bronchial hyper-responsiveness, 68

calcimimetic agent, 726
calcium sensitizer, 412
calcium-sensing receptors, 726
cancer, 416
cancer chemotherapy, 44
cardiovascular disease prevention, 640
case-report, 616
cetirizine, 402
children, 146, 735
chronic obstructive pulmonary disease, 388
cisplatin, 756
clinical outcome, 622
clinical trials, 54, 86, 640
combination therapy, 93, 253
compliance, 188
congenital toxoplasmosis, 735
contractile function, 237
converting enzyme inhibitors, 720
co-prescription, 337
coronary heart disease, 640
cost, 188
coumarin anticoagulants, 522
COX-2 inhibitors, 337
creatine phosphokinase, 525
CYP1A2, 349, 495
CYP2C19, 487
CYP2C8, 441
CYP2C9, 473
CYP2D6, 287, 456, 464, 473, 495, 569, 652, 785
CYP3A, 244
CYP3A4, 44, 105, 287, 448, 464, 473, 495
cytochrome P450, 162

darifenacin, 170
data mining, 127
dementia, 15
dextromethorphan, 456
diastolic blood pressure, 100
diet, 199
dihydroartemisinin, 93, 253, 529
diuretic resistance, 622
docetaxel, 44
doping control, 62
drug action, 373
drug delivery, 15
drug dependence, 742
Drug Information Services/standards, 80
drug interaction, 244, 436, 441
drug interactions, 162, 464, 473
drug metabolism, 756
drug prescribing, 121, 231
drug safety, 86
drug utilization, 86
drug utilization review, 500
drug-related problems, 611
duloxetine, 54, 652
dysgeusia, 807

effectiveness, 86
elderly, 54
elderly patients, 231
electroencephalogram, 153
elimination, 62, 349
endothelins, 720
end-stage renal disease, 726
ephedra, 552
ephedrines, 62
epirubicin, 764

familial hypercholesterolaemia, 525
fexofenodine, 714
fluconazole, 773
fluoroquinolones, 563
fluticasone propionate, 388
fluvoxamine, 487
food, 586
food effects, 218
formoterol, 68
fosfluconazole, 773
FTY720, 586
furosemide responsiveness, 622

gender, 37
general practitioner, 328
generalized additive model, 657
genotype, 68, 287, 456, 487
ginseng, 592
G-protein-coupled receptors, 373
grapefruit juice, 448
GSTP1, 213
gustometry, 807

9-hydroxyrisperidone, 569
haplotype, 68
heart rate, 100, 632
herb–drug interactions, 592
histamine H1-receptor antagonist, 714
HMG-CoA reductase inhibitor, 640
hospital admissions, 611
hospitalisation, 513
human, 287, 427
human and barostat, 393
hydrocodone, 287
hydromorphone, 287
hyperlipidemia, 328
hypertension, 328
hypoglycaemia, 93

imaging, 15
in vitro, 287, 349
incidence, 328
inhaled corticosteroids, 388
intensive care unit, 135
interaction, 181
Internet, 80
intervention, 328

© 2004 Blackwell Publishing Ltd

intestinal absorption, 600
intramuscular injection, 146
intravenous tyramine, 657
irreversible binding, 756

justice, 695

knowledge discovery in databases, 127
KRN 1493, 726

lactulose, 522
leflunomide, 790
letter, 328
leukaemia inhibitory factor (LIF), 576
leukotriene CysLT1-receptor antagonist, 714
levofloxacin, 563
levosimendan, 412
limited sampling, 764
lipid lowering drug, 328
lipids, 199, 640
liver disease, 344
liver function, 44
liver function tests, 199
liver microsomes, 287
liver transplantation, 298
long-acting β_2-adrenoceptor agonist, 68
lorazepam, 135

malaria, 146, 253
MDR-1, 569
medication, 513
mefloquine, 506
mental stress, 545
meta-analysis, 616, 640
metabolic ratio, 456
metabolism, 412, 742
metabolite, 170
methacholine PD_{20}, 68
methadone, 600, 742
microdialysis, 427, 563
midazolam, 135
miosis, 600
misuse, 798
molecular genetics, 213
montelukast, 714
morphine, 427
motilin, 393
moxonidine, 545
muscle pains, 525

N-acetyltransferase 2, 495
nasal challenge, 714
natriuretic peptides, 27
N-didesmethyl-tam, 105
neuropsychiatric effects, 506
nifedipine controlled-release, 632
nifedipine retard, 632
nitric oxide, 209
non-adherence, 611, 622
NONMEM, 576
norhydrocodone, 287
NSAIDs, 337
Nuremberg Code, 695

omeprazole, 487
oral anticoagulation, 798
Oral contraception, 244
oral contraceptive steroids, 279
overanticoagulation, 522
oxidation injury, 525

paediatric population pharmacokinetics, 402
paediatrics, 611
parathyroid hormone, 726
passive smoking, 37
patient, 328
peak nasal inspiratory flow, 714
perhexiline, 263, 456
persistent allergic rhinitis, 714
personality Type A and B, 785
P-glycoprotein, 244, 600
pharmacists, 513
pharmacodynamics, 6, 153, 162, 279, 586, 600
pharmaco-epidemiology, 506
pharmacokinetic, 162, 436
pharmacokinetics, 6, 54, 135, 218, 263, 279, 298, 344, 412, 427, 448, 586, 652, 735, 764, 773
pharmacovigilance, 127
Phase I, 76, 199
phenprocoumon, 522
phenylpropanolamine, 62
physical exercise, 545
piperaquine, 93, 253
placebo-controlled trial, 695
plasma binding, 756
plasma protein binding, 298
polymerase chain reaction, 785
polymorphism, 213
pooled population pharmacokinetic–pharmacodynamic meta-analysis, 170
population pharmacokinetic modelling, 742
population pharmacokinetics, 44, 146, 253, 416, 576, 756
population, 735
population screening, 328
posaconazole, 218
postapproval, 86
postural hypotension, 93
P-Pharm, 742
pravastatin, 181, 448
prediction, 473
predictor variable, 328
pressor response, 657
prevalence, 328
prevention, 798
probe cocktail, 162
professional athletes, 525
protease inhibitors, 436
protein binding, 529
pseudoephedrine, 62
psychotropic drugs, 464
publication bias, 695
pyrimethamine, 735
pyruvate dehydrogenase complex, 237

QT interval prolongation, 93
quinidine, 600

raltitrexed, 416
Régie de l'assurance maladie du Québec (RAMQ), 500
readmission, 513
relative potency, 170
renal impairment, 773
repaglinide, 441
research ethics, 695
rheumatoid arthritis, 790
rifampicin, 181
risperidone, 569
rosuvastatin, 279

safety, 552, 773
salbutamol, 100
salivary flow, 170
salmeterol, 68
saquinavir, 244
secondary hyperparathyroidism, 726
signal transduction, 373
sildenafil, 80, 209
smoking, 209
soft tissue infections, 563
St. John's wort, 495, 592
statin, 640
steady-state, 263
stereoselectivity, 742
stomach, 393
stroke, 15, 798
subsensitivity, 68
substrate utilization, 237
sulfadoxine, 735
Survey, 76
sympathetic activity, 545
systemic bioactivity, 388

tachyphylaxis, 657
tacrolimus, 298
tamoxifen, 105
target site pharmacokinetics, 563
tezosentan, 344
therapeutic drug monitoring, 263, 298
therapeutic range, 263
therapeutics, 373
tissue penetration, 563
tizanidine, 349
tolerance, 153, 552
tolterodine, 652
trimethoprim, 441

vasodilation, 209
Vasopeptidase inhibitors, 27

warfarin, 592
weight-loss, 552
World Medical Association, 695

xanthine oxidase, 495